In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares opened today at $5.93.
Olson noted:
“Management updated Imvexxy launch dynamics through 9/27 featuring the following metrics: 1) >14K scripts filled including >11K maintenance packs and ~3K starter packs, 2) written by >3,700 prescribers, and 3) paid for by >8K patients with 2nd paid refills in 44% of patients. Imvexxy scripts adjudicated, we are uncertain about net pricing in 3Q. Our $455K estimate for 3Q Imvexxy sales is slightly above $400K consensus (FactSet), but at this stage of launch, we expect investors to focus on the favorable script trajectory (Exhibit 2) and not on net revenues, which for now are minimal in any case. The Oct. 28 TX-001HR PDUFA is less than one month away, and we are encouraged by the company’s disclosure about FDA label negotiations.”
According to TipRanks.com, Olson is a 1-star analyst with an average return of -1.2% and a 45.4% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TherapeuticsMD with a $20.33 average price target, a 242.8% upside from current levels. In a report issued on September 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.66 and a one-year low of $4.34. Currently, TherapeuticsMD has an average volume of 2.26M.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.
Read More on TXMD:
